Insight Molecular Diagnostics Inc. (IMDX)
NASDAQ
Closed
Aug 25, 2026
Day's Range
4.3552 wk Range
2.33Overview - IMDX - Insight Molecular Diagnostics Inc.
Key Statistics
Valuation
Enterprise Value
126.23M
P/E (Trailing)
‪-2.69‬
P/E (Forward)
‪-5.40‬
PEG Ratio
‪0.05‬
Price / Sales (TTM)
‪84.65‬
Price / Book
‪-14.35‬
EV / EBITDA
‪-3.65‬
Profitability
Gross Margin
‪46.87%‬
Profit Margin
‪56.67%‬
Operating Margin
‪-3,815.06%‬
Return on Assets
‪-57.82%‬
Return on Equity
‪159.61%‬
Ownership
Shares Outstanding
32.28M
Float
10.40M
Short % of Shares Outstanding
‪6.64%‬
Held by Insiders
‪20.99%‬
Held by Institutions
‪56.42%‬
Price stats
Beta
‪1.82‬
50-Day Avg
‪4.92‬
200-Day Avg
‪5.38‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
4 analysts
Average price target
‪$ 8.33‬Shariah Compliance
Report Date: Feb 19, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - IMDX - Insight Molecular Diagnostics Inc.
Peers - IMDX - Insight Molecular Diagnostics Inc.
Peer Comparison
Compared with companies in Diagnostics & Research listed on NASDAQ.
- IMDXNASDAQInsight Molecular Diagnostics Inc.142.02MMarket Cap+42.63%52-week change-2.62P/E (Trailing)‪56.67%‬Profit Margin
- NTRANASDAQNATERA INC (Common Stock) – ticker 45E47.23BMarket Cap+50.52%52-week change-220.14P/E (Trailing)‪-7.10%‬Profit Margin
- IDXXNASDAQIDEXX Laboratories, Inc.44.07BMarket Cap-14.69%52-week change39.06P/E (Trailing)‪25.03%‬Profit Margin
- ILMNNASDAQIllumina, Inc.33.70BMarket Cap+55.77%52-week change41.01P/E (Trailing)‪18.33%‬Profit Margin
- GHNASDAQGuardant Health Inc.21.89BMarket Cap+62.08%52-week change-49.15P/E (Trailing)‪-38.32%‬Profit Margin
- MEDPNASDAQMedpace Holdings Inc.17.30BMarket Cap+24.71%52-week change36.41P/E (Trailing)‪17.66%‬Profit Margin
- ICICLRNASDAQICON plc13.38BMarket Cap-0.84%52-week change264.97P/E (Trailing)‪0.32%‬Profit Margin
Profile Summary - IMDX - Insight Molecular Diagnostics Inc.
About
Insight Molecular Diagnostics Inc. is a precision diagnostics company specializing in the development and commercialization of advanced molecular diagnostic tests for both clinical and research applications. With a core focus on transplant medicine and oncology, the company’s product portfolio includes…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
